US Patent

US7494982 — Modified oligonucleotides for telomerase inhibition

Composition of Matter · Assigned to Geron Corp · Expires 2026-12-27 · 1y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds that are oligonucleotides linked to lipids and inhibit human telomerase activity.

USPTO Abstract

Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.

Drugs covered by this patent

Patent Metadata

Patent number
US7494982
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-12-27
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Geron Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.